Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Reducing Falls with Varenicline in Hypocholinergic Parkinson Disease
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Vikas Kotagal
- Target Recruit Count
- 102
- Registration Number
- NCT06679374
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
- Conditions
- Tobacco UseTobacco CessationInsomnia
- Interventions
- Behavioral: Experimental health interventionDrug: Varenicline
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Yale University
- Target Recruit Count
- 114
- Registration Number
- NCT06609369
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
The Avenues Study: Dual Use Cessation
- Conditions
- Smoking CessationElectronic Cigarette Use
- Interventions
- Drug: Nicotine patchDrug: VareniclineBehavioral: Dual Focused Cessation CounselingBehavioral: Smoking Focused Cessation Counseling
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 500
- Registration Number
- NCT06474299
- Locations
- 🇺🇸
University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States
Tobacco Treatment Comparison for Cancer Care
- Conditions
- CancerSmoking Cessation
- Interventions
- Drug: Transdermal Nicotine PatchDrug: VareniclineBehavioral: Standard Telephone CounselingBehavioral: Cancer-Targeted Telephone CounselingOther: Mailed Information about Standard Care Resources
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 52
- Registration Number
- NCT06218823
- Locations
- 🇺🇸
UW Carbone Cancer Center, Madison, Wisconsin, United States
Project HOPES: Healthy Options for Pain and Ending Smoking. A Program for Cancer Survivors.
- Conditions
- PainSmoking Cessation
- Interventions
- Other: Smoking cessation and pain management interventionDrug: Varenicline
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT06029907
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
- Conditions
- Cigarette SmokingSmoking CessationE-Cigarette Use
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Yale University
- Target Recruit Count
- 40
- Registration Number
- NCT06027840
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
- Conditions
- HivAlcohol Use DisorderTobacco Use Disorder
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 30
- Registration Number
- NCT06006143
- Locations
- 🇺🇸
Atlanta VA Medical Center, Decatur, Georgia, United States
V+PSF-M for Tobacco Cessation in HIV Care in India
- Conditions
- Smoking, TobaccoSmoking CessationHuman Immunodeficiency Virus
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 400
- Registration Number
- NCT05786547
- Locations
- 🇮🇳
VHS Infectious Disease Medical Centre, CART Clinical Research Site, Chennai, Tamil Nadu, India
🇺🇸University of Colorado, Aurora, Colorado, United States
Botswana Smoking and Abstinence Reinforcement Trial
- Conditions
- Smoking CessationHiv
- Interventions
- Behavioral: Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)Drug: Varenicline
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 750
- Registration Number
- NCT05694637
- Locations
- 🇧🇼
Tutume Primary Hospital, Tutume, Central, Botswana
🇧🇼Masego Clinic, Francistown, Central, Botswana
🇧🇼Sefhare Primary Hospital, Sefhare, Central, Botswana
Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes
- Conditions
- HivTobacco Use
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT05642715
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.